Separating vendor qualification from clinical decisions
Most pain management and physical medicine groups keep two questions distinct: whether a supplier can produce adequate documentation (certificate of analysis, donor eligibility summary, lot release record) and whether a specific use fits the practice's own clinical and regulatory framework.
Precision Biologics answers the first question by releasing that documentation to verified accounts; the second question stays with the treating physician and the practice's own counsel, since whether a Wharton's jelly use meets the conditions in 21 CFR 1271.10, or how an exosome product offered outside the 361 framework is used, is not something a distributor determines.
Visalia
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
28- Pain Medicine
- 13
- Physical Medicine & Rehabilitation
- 15
Cold-chain shipping into the Central Valley
Cryopreserved Wharton's jelly and exosome formats are shipped overnight on dry ice in validated containers and need to move into -80 degree C storage promptly after delivery; lyophilized formats are shelf-stable and are handled according to the insert supplied with each lot. A practice's receiving process should include logging the lot identifier against the patient record so each unit stays traceable.
Confirming the practice's own standing
Before adding a new biologics line, a California practice typically confirms its own standing with the Medical Board of California and reviews the purchase with counsel. That step sits outside Precision Biologics' account verification, which confirms an NPI number and licensure documentation but does not evaluate a practice's specific intended use.
Account setup
Verification requires the ordering provider's NPI number. Once verified, a practice can request documentation for a specific lot and schedule a physician-level call to go over that documentation; the call covers specifications and paperwork, not treatment recommendations.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Is the 28-provider figure specific to pain management alone?+
No. It combines two taxonomies: 13 providers registered under Pain Medicine and 15 under Physical Medicine & Rehabilitation, both with a primary practice location in Visalia, as recorded in NPPES on 2026-10-27.
Can Precision Biologics tell us whether a product fits a specific use in our practice?+
No. That determination belongs to the treating physician and the practice's own regulatory counsel. Precision Biologics supplies product and documentation, not clinical advice.
How fast do cryopreserved shipments arrive?+
Cryopreserved formats ship overnight on dry ice in validated containers; exact transit depends on the carrier and should be confirmed at order time, with staff available to move product into -80 degree C storage on arrival.